Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Geneva Foundation for Medical Education and Research
Euro Pub
ICMJE
world cat
journal seek genamics
j-gate
esji (eurasian scientific journal index)
Useful Links
Recommended Journals
Related Subjects
Share This Page
Novel Angiotensin Receptor Blocker, Azilsartan induces oxidative stress and NFkB-mediated apoptosis in Hepatocellular Carcinoma cell line HepG2
Joint Event on 15th International Congress on American Pathology and Oncology Research & International Conference on Microbial Genetics and Molecular Microbiology
Mohammad Ali Eghbal, Ahmad Yari Khosroushahi, Elham Ahmadian, Aziz Eftekhari, Hossein Babaei and Safar Farajni
Overexpression of renin-angiotensin system (RAS) and nuclear factor-kappaB (NF-kB) has a key role in various cancers. Blockade
of RAS and NF-kB pathway has been suggested to reduce cancer cell proliferation. This study aimed to investigate the role of
angiotensin II and NF-kB pathway in liver hepatocellular carcinoma cell line (HepG2) proliferation by using azilsartan (as a novel Ag
II antagonist) and Bay11-7082 (as NF-kB inhibitor). HepG2 cells were treated with different concentrations of azilsartan and Bay11-
7082. Cytotoxicity was determined after 24, 48, and 72 h by MTT assay. Reactive oxygen spices (ROS) generation and cytochrome c
release were measured following azilsartan and Bay11-7082 treatment. Apoptosis was analyzed qualitatively by DAPI staining and
quantitatively through flow cytometry methodologies and Bax and Bcl-2 mRNA and protein levels were assessed by real-time PCR
and ELISA methods, respectively. The cytotoxic effects of different concentration of azilsartan and Bay11-7082 on HepG2 cells were
observed as a reduction in cell viability, ROS formation, cytochrome c release, and apoptosis induction. These effects were found to
correlate with a shift in Bax level and a downward trend in the expression of Bcl-2. These findings suggest that azilsartan and Bay11-
7082 in combination or alone have strong potential for development as an agent for prevention against liver cancer after further
studies.